Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.
Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer’s disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.
A member of a class of drugs that are widely prescribed for abnormal behavioral symptoms in Alzheimer’s – but not often studied in people with the degenerative brain disease – proved to be effective and well tolerated in treating agitation in people with severe Alzheimer’s
Scientists funded by the UK's largest biomedical research charity, The Wellcome Trust, have developed a drink that enhances the effectiveness of medication given to treat psychiatric illnesses such as mania and schizophrenia.
Solvay has re-evaluated the commercial potential of bifeprunox, a Solvay compound in clinical development for the treatment of schizophrenia . Bifeprunox additionally has the potential to be developed in other disorders, i.e. bipolar disorder.
Patients with schizophrenia who fail to take their medicines as prescribed are over one-and-a-half times as likely to be rehospitalised and use in-patient services as patients who stick to their medication regimen. Non-adherence predicted an excess annual cost per patient of £5000 for total service use.
Patients with severe and persistent mental illness treated with antipsychotic medications reported positive changes in diet, exercise, stress management, improved sleep, and increased confidence in maintaining these lifestyle changes after participating in the Solutions for Wellness Personalized Program (SFWPP), new data show.
Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins.
Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.
Researchers at Duke University Medical Center have found that a new generation of medications called "atypical antipsychotics" can significantly lower the risk of violent behavior in people with schizophrenia who are being treated in community-based centers.
Physicians have a new fast-acting option for controlling the potentially crippling effects of acute agitation in patients suffering with schizophrenia and bipolar mania. The U.S. Food and Drug Administration (FDA) has approved Zyprexa® IntraMuscular (olanzapine for injection), an injectable form of Lilly's top-selling medication.